Non-muscle Invasive Bladder Cancer Therapeutics Market, Global Outlook and Forecast 2022-2028
This report contains market size and forecasts of Non-muscle Invasive Bladder Cancer Therapeutics in Global, including the following market information:
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non-muscle Invasive Bladder Cancer Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Intravesical Chemotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non-muscle Invasive Bladder Cancer Therapeutics include F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Eli Lilly and Company and Merck & Co., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-muscle Invasive Bladder Cancer Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-muscle Invasive Bladder Cancer Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, by Type, 2021 (%)
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, by Application, 2021 (%)
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
The report also provides analysis of leading market participants including:
Key companies Non-muscle Invasive Bladder Cancer Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non-muscle Invasive Bladder Cancer Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Non-muscle Invasive Bladder Cancer Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Intravesical Chemotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Non-muscle Invasive Bladder Cancer Therapeutics include F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., GlaxoSmithKline plc., Sanofi S.A., Novartis AG, Eli Lilly and Company and Merck & Co., etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-muscle Invasive Bladder Cancer Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-muscle Invasive Bladder Cancer Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, by Type, 2021 (%)
- Intravesical Chemotherapy
- Intravesical Immunotherapy
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, by Application, 2021 (%)
- Hospital
- Ambulatory Surgery Center
- Others
Global Non-muscle Invasive Bladder Cancer Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies Non-muscle Invasive Bladder Cancer Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Non-muscle Invasive Bladder Cancer Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- AstraZeneca
- Pfizer Inc.
- GlaxoSmithKline plc.
- Sanofi S.A.
- Novartis AG
- Eli Lilly and Company
- Merck & Co.
- Viventia Bio Inc.
- Celgene Corporation
- Spectrum Pharmaceuticals, Inc.
- Herantis Pharma Plc.
- Taris Biomedical LLC
- Prometic Life Sciences Inc.
- Telormediz S.A.
- Heat Biologics
- Altor BioScience
- Ferring B.V.
- Cold Genesys Inc.
1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS
1.1 Non-muscle Invasive Bladder Cancer Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL NON-MUSCLE INVASIVE BLADDER CANCER THERAPEUTICS OVERALL MARKET SIZE
2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size: 2021 VS 2028
2.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market
3.2 Top Global Non-muscle Invasive Bladder Cancer Therapeutics Companies Ranked by Revenue
3.3 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Non-muscle Invasive Bladder Cancer Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Non-muscle Invasive Bladder Cancer Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Non-muscle Invasive Bladder Cancer Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Markets, 2021 & 2028
4.1.2 Intravesical Chemotherapy
4.1.3 Intravesical Immunotherapy
4.2 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2022
4.2.2 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2023-2028
4.2.3 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Ambulatory Surgery Center
5.1.4 Others
5.2 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2022
5.2.2 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2023-2028
5.2.3 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2022
6.2.2 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2023-2028
6.2.3 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028
6.3.2 US Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.3.3 Canada Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.3.4 Mexico Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028
6.4.2 Germany Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4.3 France Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4.4 U.K. Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4.5 Italy Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4.6 Russia Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4.7 Nordic Countries Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4.8 Benelux Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028
6.5.2 China Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.5.3 Japan Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.5.4 South Korea Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.5.5 Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.5.6 India Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028
6.6.2 Brazil Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.6.3 Argentina Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028
6.7.2 Turkey Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.7.3 Israel Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.7.4 Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.7.5 UAE Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 F. Hoffmann-La Roche Ltd.
7.1.1 F. Hoffmann-La Roche Ltd. Corporate Summary
7.1.2 F. Hoffmann-La Roche Ltd. Business Overview
7.1.3 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.1.4 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.1.5 F. Hoffmann-La Roche Ltd. Key News
7.2 Bristol-Myers Squibb Company
7.2.1 Bristol-Myers Squibb Company Corporate Summary
7.2.2 Bristol-Myers Squibb Company Business Overview
7.2.3 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.2.4 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.2.5 Bristol-Myers Squibb Company Key News
7.3 AstraZeneca
7.3.1 AstraZeneca Corporate Summary
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.3.4 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.3.5 AstraZeneca Key News
7.4 Pfizer Inc.
7.4.1 Pfizer Inc. Corporate Summary
7.4.2 Pfizer Inc. Business Overview
7.4.3 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.4.4 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.4.5 Pfizer Inc. Key News
7.5 GlaxoSmithKline plc.
7.5.1 GlaxoSmithKline plc. Corporate Summary
7.5.2 GlaxoSmithKline plc. Business Overview
7.5.3 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.5.4 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.5.5 GlaxoSmithKline plc. Key News
7.6 Sanofi S.A.
7.6.1 Sanofi S.A. Corporate Summary
7.6.2 Sanofi S.A. Business Overview
7.6.3 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.6.4 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.6.5 Sanofi S.A. Key News
7.7 Novartis AG
7.7.1 Novartis AG Corporate Summary
7.7.2 Novartis AG Business Overview
7.7.3 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.7.4 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.7.5 Novartis AG Key News
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Corporate Summary
7.8.2 Eli Lilly and Company Business Overview
7.8.3 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.8.4 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.8.5 Eli Lilly and Company Key News
7.9 Merck & Co.
7.9.1 Merck & Co. Corporate Summary
7.9.2 Merck & Co. Business Overview
7.9.3 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.9.4 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.9.5 Merck & Co. Key News
7.10 Viventia Bio Inc.
7.10.1 Viventia Bio Inc. Corporate Summary
7.10.2 Viventia Bio Inc. Business Overview
7.10.3 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.10.4 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.10.5 Viventia Bio Inc. Key News
7.11 Celgene Corporation
7.11.1 Celgene Corporation Corporate Summary
7.11.2 Celgene Corporation Business Overview
7.11.3 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.11.4 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.11.5 Celgene Corporation Key News
7.12 Spectrum Pharmaceuticals, Inc.
7.12.1 Spectrum Pharmaceuticals, Inc. Corporate Summary
7.12.2 Spectrum Pharmaceuticals, Inc. Business Overview
7.12.3 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.12.4 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.12.5 Spectrum Pharmaceuticals, Inc. Key News
7.13 Herantis Pharma Plc.
7.13.1 Herantis Pharma Plc. Corporate Summary
7.13.2 Herantis Pharma Plc. Business Overview
7.13.3 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.13.4 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.13.5 Herantis Pharma Plc. Key News
7.14 Taris Biomedical LLC
7.14.1 Taris Biomedical LLC Corporate Summary
7.14.2 Taris Biomedical LLC Business Overview
7.14.3 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.14.4 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.14.5 Taris Biomedical LLC Key News
7.15 Prometic Life Sciences Inc.
7.15.1 Prometic Life Sciences Inc. Corporate Summary
7.15.2 Prometic Life Sciences Inc. Business Overview
7.15.3 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.15.4 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.15.5 Prometic Life Sciences Inc. Key News
7.16 Telormediz S.A.
7.16.1 Telormediz S.A. Corporate Summary
7.16.2 Telormediz S.A. Business Overview
7.16.3 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.16.4 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.16.5 Telormediz S.A. Key News
7.17 Heat Biologics
7.17.1 Heat Biologics Corporate Summary
7.17.2 Heat Biologics Business Overview
7.17.3 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.17.4 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.17.5 Heat Biologics Key News
7.18 Altor BioScience
7.18.1 Altor BioScience Corporate Summary
7.18.2 Altor BioScience Business Overview
7.18.3 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.18.4 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.18.5 Altor BioScience Key News
7.19 Ferring B.V.
7.19.1 Ferring B.V. Corporate Summary
7.19.2 Ferring B.V. Business Overview
7.19.3 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.19.4 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.19.5 Ferring B.V. Key News
7.20 Cold Genesys Inc.
7.20.1 Cold Genesys Inc. Corporate Summary
7.20.2 Cold Genesys Inc. Business Overview
7.20.3 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.20.4 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.20.5 Cold Genesys Inc. Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
1.1 Non-muscle Invasive Bladder Cancer Therapeutics Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 GLOBAL NON-MUSCLE INVASIVE BLADDER CANCER THERAPEUTICS OVERALL MARKET SIZE
2.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size: 2021 VS 2028
2.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 COMPANY LANDSCAPE
3.1 Top Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market
3.2 Top Global Non-muscle Invasive Bladder Cancer Therapeutics Companies Ranked by Revenue
3.3 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Companies
3.4 Top 3 and Top 5 Non-muscle Invasive Bladder Cancer Therapeutics Companies in Global Market, by Revenue in 2021
3.5 Global Companies Non-muscle Invasive Bladder Cancer Therapeutics Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market
3.6.1 List of Global Tier 1 Non-muscle Invasive Bladder Cancer Therapeutics Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Companies
4 MARKET SIGHTS BY PRODUCT
4.1 Overview
4.1.1 by Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size Markets, 2021 & 2028
4.1.2 Intravesical Chemotherapy
4.1.3 Intravesical Immunotherapy
4.2 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue & Forecasts
4.2.1 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2022
4.2.2 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2023-2028
4.2.3 By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
5 SIGHTS BY APPLICATION
5.1 Overview
5.1.1 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2021 & 2028
5.1.2 Hospital
5.1.3 Ambulatory Surgery Center
5.1.4 Others
5.2 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue & Forecasts
5.2.1 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2022
5.2.2 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2023-2028
5.2.3 By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
6 SIGHTS BY REGION
6.1 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2021 & 2028
6.2 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue & Forecasts
6.2.1 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2022
6.2.2 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2023-2028
6.2.3 By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028
6.3.2 US Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.3.3 Canada Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.3.4 Mexico Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028
6.4.2 Germany Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4.3 France Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4.4 U.K. Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4.5 Italy Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4.6 Russia Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4.7 Nordic Countries Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.4.8 Benelux Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028
6.5.2 China Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.5.3 Japan Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.5.4 South Korea Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.5.5 Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.5.6 India Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028
6.6.2 Brazil Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.6.3 Argentina Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028
6.7.2 Turkey Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.7.3 Israel Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.7.4 Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
6.7.5 UAE Non-muscle Invasive Bladder Cancer Therapeutics Market Size, 2017-2028
7 PLAYERS PROFILES
7.1 F. Hoffmann-La Roche Ltd.
7.1.1 F. Hoffmann-La Roche Ltd. Corporate Summary
7.1.2 F. Hoffmann-La Roche Ltd. Business Overview
7.1.3 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.1.4 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.1.5 F. Hoffmann-La Roche Ltd. Key News
7.2 Bristol-Myers Squibb Company
7.2.1 Bristol-Myers Squibb Company Corporate Summary
7.2.2 Bristol-Myers Squibb Company Business Overview
7.2.3 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.2.4 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.2.5 Bristol-Myers Squibb Company Key News
7.3 AstraZeneca
7.3.1 AstraZeneca Corporate Summary
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.3.4 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.3.5 AstraZeneca Key News
7.4 Pfizer Inc.
7.4.1 Pfizer Inc. Corporate Summary
7.4.2 Pfizer Inc. Business Overview
7.4.3 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.4.4 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.4.5 Pfizer Inc. Key News
7.5 GlaxoSmithKline plc.
7.5.1 GlaxoSmithKline plc. Corporate Summary
7.5.2 GlaxoSmithKline plc. Business Overview
7.5.3 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.5.4 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.5.5 GlaxoSmithKline plc. Key News
7.6 Sanofi S.A.
7.6.1 Sanofi S.A. Corporate Summary
7.6.2 Sanofi S.A. Business Overview
7.6.3 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.6.4 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.6.5 Sanofi S.A. Key News
7.7 Novartis AG
7.7.1 Novartis AG Corporate Summary
7.7.2 Novartis AG Business Overview
7.7.3 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.7.4 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.7.5 Novartis AG Key News
7.8 Eli Lilly and Company
7.8.1 Eli Lilly and Company Corporate Summary
7.8.2 Eli Lilly and Company Business Overview
7.8.3 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.8.4 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.8.5 Eli Lilly and Company Key News
7.9 Merck & Co.
7.9.1 Merck & Co. Corporate Summary
7.9.2 Merck & Co. Business Overview
7.9.3 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.9.4 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.9.5 Merck & Co. Key News
7.10 Viventia Bio Inc.
7.10.1 Viventia Bio Inc. Corporate Summary
7.10.2 Viventia Bio Inc. Business Overview
7.10.3 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.10.4 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.10.5 Viventia Bio Inc. Key News
7.11 Celgene Corporation
7.11.1 Celgene Corporation Corporate Summary
7.11.2 Celgene Corporation Business Overview
7.11.3 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.11.4 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.11.5 Celgene Corporation Key News
7.12 Spectrum Pharmaceuticals, Inc.
7.12.1 Spectrum Pharmaceuticals, Inc. Corporate Summary
7.12.2 Spectrum Pharmaceuticals, Inc. Business Overview
7.12.3 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.12.4 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.12.5 Spectrum Pharmaceuticals, Inc. Key News
7.13 Herantis Pharma Plc.
7.13.1 Herantis Pharma Plc. Corporate Summary
7.13.2 Herantis Pharma Plc. Business Overview
7.13.3 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.13.4 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.13.5 Herantis Pharma Plc. Key News
7.14 Taris Biomedical LLC
7.14.1 Taris Biomedical LLC Corporate Summary
7.14.2 Taris Biomedical LLC Business Overview
7.14.3 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.14.4 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.14.5 Taris Biomedical LLC Key News
7.15 Prometic Life Sciences Inc.
7.15.1 Prometic Life Sciences Inc. Corporate Summary
7.15.2 Prometic Life Sciences Inc. Business Overview
7.15.3 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.15.4 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.15.5 Prometic Life Sciences Inc. Key News
7.16 Telormediz S.A.
7.16.1 Telormediz S.A. Corporate Summary
7.16.2 Telormediz S.A. Business Overview
7.16.3 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.16.4 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.16.5 Telormediz S.A. Key News
7.17 Heat Biologics
7.17.1 Heat Biologics Corporate Summary
7.17.2 Heat Biologics Business Overview
7.17.3 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.17.4 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.17.5 Heat Biologics Key News
7.18 Altor BioScience
7.18.1 Altor BioScience Corporate Summary
7.18.2 Altor BioScience Business Overview
7.18.3 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.18.4 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.18.5 Altor BioScience Key News
7.19 Ferring B.V.
7.19.1 Ferring B.V. Corporate Summary
7.19.2 Ferring B.V. Business Overview
7.19.3 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.19.4 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.19.5 Ferring B.V. Key News
7.20 Cold Genesys Inc.
7.20.1 Cold Genesys Inc. Corporate Summary
7.20.2 Cold Genesys Inc. Business Overview
7.20.3 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Major Product Offerings
7.20.4 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global Market (2017-2022)
7.20.5 Cold Genesys Inc. Key News
8 CONCLUSION
9 APPENDIX
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES
Table 1. Non-muscle Invasive Bladder Cancer Therapeutics Market Opportunities & Trends in Global Market
Table 2. Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers in Global Market
Table 3. Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints in Global Market
Table 4. Key Players of Non-muscle Invasive Bladder Cancer Therapeutics in Global Market
Table 5. Top Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Non-muscle Invasive Bladder Cancer Therapeutics Product Type
Table 9. List of Global Tier 1 Non-muscle Invasive Bladder Cancer Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. F. Hoffmann-La Roche Ltd. Corporate Summary
Table 31. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 32. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Bristol-Myers Squibb Company Corporate Summary
Table 34. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 35. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. AstraZeneca Corporate Summary
Table 37. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 38. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Pfizer Inc. Corporate Summary
Table 40. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 41. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. GlaxoSmithKline plc. Corporate Summary
Table 43. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 44. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Sanofi S.A. Corporate Summary
Table 46. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 47. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Novartis AG Corporate Summary
Table 49. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 50. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Eli Lilly and Company Corporate Summary
Table 52. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 53. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Merck & Co. Corporate Summary
Table 55. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 56. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. Viventia Bio Inc. Corporate Summary
Table 58. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 59. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 60. Celgene Corporation Corporate Summary
Table 61. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 62. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 63. Spectrum Pharmaceuticals, Inc. Corporate Summary
Table 64. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 65. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 66. Herantis Pharma Plc. Corporate Summary
Table 67. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 68. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 69. Taris Biomedical LLC Corporate Summary
Table 70. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 71. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 72. Prometic Life Sciences Inc. Corporate Summary
Table 73. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 74. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 75. Telormediz S.A. Corporate Summary
Table 76. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 77. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 78. Heat Biologics Corporate Summary
Table 79. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 80. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 81. Altor BioScience Corporate Summary
Table 82. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 83. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 84. Ferring B.V. Corporate Summary
Table 85. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 86. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 87. Cold Genesys Inc. Corporate Summary
Table 88. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 89. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 1. Non-muscle Invasive Bladder Cancer Therapeutics Market Opportunities & Trends in Global Market
Table 2. Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers in Global Market
Table 3. Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints in Global Market
Table 4. Key Players of Non-muscle Invasive Bladder Cancer Therapeutics in Global Market
Table 5. Top Non-muscle Invasive Bladder Cancer Therapeutics Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Companies, 2017-2022
Table 8. Global Companies Non-muscle Invasive Bladder Cancer Therapeutics Product Type
Table 9. List of Global Tier 1 Non-muscle Invasive Bladder Cancer Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-muscle Invasive Bladder Cancer Therapeutics Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Non-muscle Invasive Bladder Cancer Therapeutics Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2023-2028
Table 30. F. Hoffmann-La Roche Ltd. Corporate Summary
Table 31. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 32. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 33. Bristol-Myers Squibb Company Corporate Summary
Table 34. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 35. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 36. AstraZeneca Corporate Summary
Table 37. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 38. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 39. Pfizer Inc. Corporate Summary
Table 40. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 41. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 42. GlaxoSmithKline plc. Corporate Summary
Table 43. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 44. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 45. Sanofi S.A. Corporate Summary
Table 46. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 47. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 48. Novartis AG Corporate Summary
Table 49. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 50. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 51. Eli Lilly and Company Corporate Summary
Table 52. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 53. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 54. Merck & Co. Corporate Summary
Table 55. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 56. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 57. Viventia Bio Inc. Corporate Summary
Table 58. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 59. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 60. Celgene Corporation Corporate Summary
Table 61. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 62. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 63. Spectrum Pharmaceuticals, Inc. Corporate Summary
Table 64. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 65. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 66. Herantis Pharma Plc. Corporate Summary
Table 67. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 68. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 69. Taris Biomedical LLC Corporate Summary
Table 70. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 71. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 72. Prometic Life Sciences Inc. Corporate Summary
Table 73. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 74. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 75. Telormediz S.A. Corporate Summary
Table 76. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 77. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 78. Heat Biologics Corporate Summary
Table 79. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 80. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 81. Altor BioScience Corporate Summary
Table 82. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 83. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 84. Ferring B.V. Corporate Summary
Table 85. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 86. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
Table 87. Cold Genesys Inc. Corporate Summary
Table 88. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product Offerings
Table 89. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (US$, Mn), (2017-2022)
LIST OF FIGURES
Figure 1. Non-muscle Invasive Bladder Cancer Therapeutics Segment by Type in 2021
Figure 2. Non-muscle Invasive Bladder Cancer Therapeutics Segment by Application in 2021
Figure 3. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-muscle Invasive Bladder Cancer Therapeutics Revenue in 2021
Figure 8. By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 1. Non-muscle Invasive Bladder Cancer Therapeutics Segment by Type in 2021
Figure 2. Non-muscle Invasive Bladder Cancer Therapeutics Segment by Application in 2021
Figure 3. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-muscle Invasive Bladder Cancer Therapeutics Revenue in 2021
Figure 8. By Type - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 9. By Application - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 10. By Region - Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 11. By Country - North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 12. US Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 16. Germany Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 17. France Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 24. China Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 28. India Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 30. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share, 2017-2028
Figure 33. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Non-muscle Invasive Bladder Cancer Therapeutics Revenue, (US$, Mn), 2017-2028
Figure 37. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
